SKYRIZI RESULTS

The FIRST AND ONLY IL-23i for Crohn’s That Can Deliver CLINICAL REMISSION and ENDOSCOPIC IMPROVEMENT

IL-23 inhibitor (IL-23i) with clinical remission and endoscopic response co-primary measures in label at both 12 and 52 weeks.

RESULTS You Can FEEL

Significant symptom relief as early as 4 weeks, including:

  • less abdominal pain 
  • fewer bowel movements

The majority of people on SKYRIZI achieved long-lasting
remission at 1 year.*

*Clinical remission was measured at 52 weeks.

And Your Doctor Can SEE

Monitoring endoscopic changes is an important part of managing your Crohn’s and reaching your treatment goals. That’s because, even if you’re feeling better, damaging inflammation may continue to occur in the intestinal lining. Your doctor can see this on an endoscopy. 

4 out of 10 People

Endoscopic remission was achieved in 4/10 people on SKYRIZI—meaning little to no visible evidence of active Crohn’s—at 1 year.†‡

Endoscopic remission was achieved in 4/10 people on SKYRIZI—meaning little to no visible evidence of active Crohn’s at 1 year.†‡  

†Based on areas that were assessed on endoscopy.

‡In the clinical trial, this measure was not tested for a difference between SKYRIZI and placebo.

Dosing Information: Adults with Crohn’s disease will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as an injection under the skin (subcutaneous injection) using the prefilled cartridge with On-Body Injector (OBI).  SKYRIZI is available as 180 mg or 360 mg maintenance dosage options. Your doctor will decide what maintenance dose is right for you.

When I started taking SKYRIZI, I started noticing results four weeks in.

Kade, a real Crohn’s patient using SKYRIZI

Discover more of Kade’s story

PATIENTS WHO ACHIEVED CLINICAL REMISSION ON SKYRIZI

meaning few or no symptoms

CD-1 Study at Week 12 600 mg IV infusion

45%

25% placebo

CD-2 Study at Week 12 600 mg IV infusion

42%

20% placebo

CD-3 Study at Week 52 180 mg/1.2 mL maintenance injection

61%

46% placebo

CD-3 Study at Week 52 360 mg/2.4 mL maintenance injection

57%

46% placebo

PATIENTS WHO ACHIEVED ENDOSCOPIC IMPROVEMENT ON SKYRIZI

meaning at least a 50% visible improvement of the intestinal lining

CD-1 Study at Week 12600 mg IV infusion

40%

12% placebo

CD-2 Study at Week 12 600 mg IV infusion

29%

11% placebo

CD-3 Study at Week 52 180 mg/1.2 mL maintenance injection

50%

22% placebo

CD-3 Study at Week 52 360 mg/2.4 mL maintenance injection

48%

22% placebo

Individual results may vary. Ask your doctor about SKYRIZI.

CD-1 (n=336) and CD-3 (n=252) clinical studies were a mixed population of patients with or without prior biologic failure. CD-2 (n=191) clinical study consisted of patients who failed at least one biologic.

CD-3 evaluated SKYRIZI 180 mg (n=135) and SKYRIZI 360 mg (n=117) maintenance doses in patients who had achieved clinical response (a reduction in CDAI of at least 100 points from baseline) after completion of 12-week SKYRIZI induction treatment (CD-1 and CD-2).

Hear From a SKYRIZI Patient

People living with Crohn’s disease understand how much impact it can have. Meet Kade and see how he took control of his moderate to severe Crohn’s with SKYRIZI.

Transcript
View Transcript

Quick Poll

Have you ever taken a biologic to treat your moderate to severe Crohn’s disease?

Yes

Interested in learning about SKYRIZI? Use our guide to start a conversation with your doctor about your treatment plan.

Begin the Guide

No

Did you know there are different types of treatment options? Read on to learn about treatment types.

See Types of Treatment

Up Next

PREPARE
FOR YOUR APPOINTMENT

Find suggestions on talking with your doctor about your symptoms and treatment options.

See What Questions to Ask

Recommended for You

HOW SKYRIZI
WORKS

Understand the science behind this treatment for Crohn’s.

Get Answers

SKYRIZI
DOSING

Learn how SKYRIZI can be administered at home after 3 starter doses and proper training by a healthcare professional.

Get Dosing Details